Accesso libero

6th Hellenic Congress of Oncology

| 07 apr 2023
Forum of Clinical Oncology's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Pubblicato online: 07 apr 2023
Pagine: 1 - 59
DOI: https://doi.org/10.2478/fco-2022-0009
© 2022 Published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

The variation of PTEN, P-PTEN and DJ-1 biomarker levels in oncology patients before and during immunotherapy depends on the corresponding levels in healthy adults.
The variation of PTEN, P-PTEN and DJ-1 biomarker levels in oncology patients before and during immunotherapy depends on the corresponding levels in healthy adults.

Figure 2

The variation of the DJ-1 biomarker levels regarding the histological type of the cancer before and after performing immunotherapy.
The variation of the DJ-1 biomarker levels regarding the histological type of the cancer before and after performing immunotherapy.

Figure 3

The variation of the levels of the PTEN biomarker regarding the histological type of the neoplasm before and after performing the immunotherapy.
The variation of the levels of the PTEN biomarker regarding the histological type of the neoplasm before and after performing the immunotherapy.

Figure 4

The variation of P-PTEN biomarker levels with respect to the histological type of the neoplasm prior and during immunotherapy.
The variation of P-PTEN biomarker levels with respect to the histological type of the neoplasm prior and during immunotherapy.

Figure 5

The variation of PTEN, P-PTEN AND DJ1 biomarker levels with respect to sex in cancer patients and healthy adults.
The variation of PTEN, P-PTEN AND DJ1 biomarker levels with respect to sex in cancer patients and healthy adults.

RFS according to HER2 expression
RFS according to HER2 expression

N- patients
N- patients

N+ patients
N+ patients

Patients with ductal carcinoma
Patients with ductal carcinoma

Patients with lobular / mixed ductal&lobular carcinoma
Patients with lobular / mixed ductal&lobular carcinoma

Figure 1

Localization of transfected DJ-1-GFP in HeLa cells. Nuclei were stained with PI.
Localization of transfected DJ-1-GFP in HeLa cells. Nuclei were stained with PI.

Figure 2

Localization of transfected DJ-1-GFP in U87 cells. Nuclei were stained with PI.
Localization of transfected DJ-1-GFP in U87 cells. Nuclei were stained with PI.

Figure 3

Localization of transfected DJ-1-GFP in MCF-7 cells. Nuclei were stained with PI.
Localization of transfected DJ-1-GFP in MCF-7 cells. Nuclei were stained with PI.

Figure 4

Western blotting analysis, using an anti-E-Cadherin monoclonal antibody, of extracts from MCF-7 cells that were incubated for the indicated time periods with the culture supernatants of GFP- or GFP-DJ1-overexpressed HeLa cells.
Western blotting analysis, using an anti-E-Cadherin monoclonal antibody, of extracts from MCF-7 cells that were incubated for the indicated time periods with the culture supernatants of GFP- or GFP-DJ1-overexpressed HeLa cells.

Figure 5

Western blotting analysis, using an anti-B-Catenin monoclonal antibody, of extracts from MCF-7 cells that were incubated for the indicated time periods with the culture supernatants of GFP- or GFP-DJ1-overexpressed HeLa cells.
Western blotting analysis, using an anti-B-Catenin monoclonal antibody, of extracts from MCF-7 cells that were incubated for the indicated time periods with the culture supernatants of GFP- or GFP-DJ1-overexpressed HeLa cells.

j.fco-2022-0009.tab.006

HER2-Surgery
HER2-0 HER2-1 HER2-2neg HER2-2pos HER2+3
HER2-core HER2-0 71.1% 26.8% 1.4% 0.7% 0.0%
HER2-1 12.9% 66.9% 17.3% 1.4% 1.4%
HER2-2neg 10.0% 35.0% 50.0% 5.0% 0.0%
HER2-2pos 0.0% 0.0% 0.0% 100.0% 0.0%
HER2+2-ND 10.0% 20.0% 65.0% 5.0% 0.0%
HER2+3 0.0% 13.3% 6.7% 20.0% 60.0%

j.fco-2022-0009.tab.005

HER2-neg to HER2-pos 7 out of 138 5.1%
HER2-0 to HER2-low 10 out of 40 25.0%

j.fco-2022-0009.tab.008

Sarcoma type site of primary sex age stage site of NGS mutation line of targeted treatment drug duration
ES Big toe foot Male 39 metastatic metastasis RAD50, BRCA2 4th Olaparib 2,5 months
uLPS ampulla of Vater Female 77 metastatic metastasis CHEK2 2nd Olaparib 1 month
MPNST unknown primary tumor Male 48 metastatic metastasis BRAF 1st Dabrafenib/Trametinib 12 months
IFT abdomen Female 68 local Primary tumor ALK 1st crizotinib 6 months ongoing
ERMS jaw Male 22 lung metastasis BRCA1 7th olaparib 1 month

Clinicopathological characteristics of patients

Median (25th–75th perc) Missing (%)
Total 1470 38 (2,6%)
Age 59 (18 – 94)
Date of Diagnosis 01/01/1994–30/12/2018
Stage 1416 54 (3,7%)
I 218 (15,4%)
II 119 (8,4%)
IIIa 39 (2,8%)
IIIb 58 (4,1%)
IIIc 774 (54,7%)
IV 208 (14,7%)
Histology 1419 51 (3,4%)
Serous 894 (63%)
Mucinous 77 (5,4%)
Clear cell 114 (8%)
Endometrioid 163 (11,5%)
Poorly differentiated 55 (3,6%)
Other 116 (8,2%)
Grade 1224 246 (16,7%)
Low (G1) 99 (8%)
High
BRCA 1/2 mutations 92 (6,3%)
Present 27 (29,3%)
Absent 65 (70,7%)
Not tested 1378 (93,7%)
Surgery 1463 7 (0,4%)
PDS 1254 (85,7%)
IDS 124 (8,5%)
None 84 (5,7%)
ECOG 1340 130 (8,8%)
0 891 (66,5%)
I 253 (17,2%)
II 123 (9,2%)
III 61 (4,6%)
IV 11 (0,8%)
989 481 (32,7%)
Median PFS (months) 37,9
Median PFS - IIIC 27,5
Median PFS - IV 24,63
Median PFS - IIIC/IV 26,89
1447 23 (1,6%)
Median OS (months) 52,04
Median OS - IIIC 45,16
Median OS - IV 31,98
Median OS – IIIC/IV 42,36

j.fco-2022-0009.tab.007

HER2-neg to HER2-pos 7 out of 301 2.3%
HER2-0 to HER2-low 40 out of 142 28.2%

j.fco-2022-0009.tab.002

CHEMOTHERAPY COST COST PER PATIENT NUMBER OF PATIENTS COST PER SESSION AVG No SESSIONS AVG AGE ΓYNAIKEΣ WOMEN AAAAAA MEN
BREAST CANCER 2007 1.597.695,04 € 10.442,45 € 153 1.316,06 € 7 61 151 2
2016 1.460.909,35 € 10.075,24 € 145 1.295,13 € 7 59,8 142 3
PANCREATIC CANCER 2007 248.681,69 € 5.920 € 42 826,19 € 7 64 13 29
2016 306.121,73 € 3.327,41 € 92 352,67 € 9 65,5 43 49

j.fco-2022-0009.tab.001

Primary tumor Incidence Gender (female) Age≥65 BMI≥30 Smoking Khorana score ≥2 Metastatic HRTAs DDIs
Pancreas 27.2 40.9 54.0 11.2 49.2 100.0 76.7 96.8 63.1
Lung 25.8 22.3 57.6 19.2 88.1 60.5 88.5 89.3 58.2
Stomach 7.1 23.8 57.1 14.3 61.2 98.0 65.9 89.8 32.7
Urological 11.6 9.5 66.3 22.5 71.3 26.3 69.3 66.3 47.5
Rectal 11.1 37.3 59.2 11.8 47.4 21.1 85.5 93.4 30.3
Breast 4.2 96.2 24.1 17.2 34.5 17.2 73.1 62.1 65.5
Ovarian 4.1 100.0 60.7 25.0 28.6 67.9 76.9 85.7 78.6
Corpus uterus 1.2 100.0 62.5 62.5 25.0 62.5 83.3 62.5 87.5
Cervix uterus 0.7 100.0 - - 80.0 80.0 80.0 100.0 100.0
Other 7.0 32.4 43.8 29.2 66.7 4.2 64.7 83.3 50.0

j.fco-2022-0009.tab.004

HER2-ResD
HER2-0 HER2-1 HER2-2neg HER2-2pos HER2+3
HER2-core HER2-0 72.5% 22.5% 2.5% 0.0% 2.5%
HER2-1 11.1% 73.6% 9.7% 0.0% 5.6%
HER2-2neg 15.4% 42.3% 34.6% 3.8% 3.8%
HER2-2pos 0.0% 33.3% 8.3% 50.0% 8.3%
HER2+3 7.4% 3.7% 3.7% 3.7% 81.5%
eISSN:
1792-362X
Lingua:
Inglese
Frequenza di pubblicazione:
4 volte all'anno
Argomenti della rivista:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology
Feed RSS della rivista